Skip to main content
رجوع
Watch Compare

Allarity Therapeutics, Inc.

جودة البيانات: 83%
ALLR
Nasdaq Manufacturing Chemicals
KWD 1.16
▼ KWD 0.01 (-0.43%)
القيمة السوقية: 18.27 M
السعر
KWD 1.16
القيمة السوقية
18.27 M
نطاق اليوم
KWD 1.13 — KWD 1.18
نطاق 52 أسبوعًا
KWD 0.62 — KWD 2.35
حجم التداول
41,115
فتح KWD 1.17
متوسط 50 يوم / 200 يوم
KWD 1.05
9.56% above
متوسط 50 يوم / 200 يوم
KWD 1.19
3.23% below

Quick Summary

النقاط الرئيسية

Negative free cash flow of -14.83 M

النمو

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

الجودة

Return on Equity
-92.90%
أقل من متوسط القطاع (-53.47%)
ROIC-82.37%
Net MarginN/A
Op. MarginN/A

الأمان

Debt / Equity
N/A
Current Ratio2.33
Interest Coverage-68.14

التقييم

PE (TTM)
-1.63
أقل من متوسط القطاع (-1.47)
P/B Ratio1.52
EV/EBITDAN/A
Dividend YieldN/A

تاريخ السعر

الاتجاهات المالية

مقارنة الأقران

مقابل وسيط قطاع Manufacturing (1364 نظير)
المقياس السهم وسيط القطاع
P/E -1.6 -1.5
P/B 1.5 1.6
ROE % -92.9 -53.5
Net Margin % — -41.5
Rev Growth 5Y % — 1.8
D/E — 0.3

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) N/A Net Income (TTM) -11.23 M
ROE -92.90% ROA -53.48%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -14.83 M
ROIC -82.37% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 2.33
Interest Coverage -68.14 Asset Turnover N/A
Working Capital 11.68 M Tangible Book Value 12.01 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -1.63 Forward P/E N/A
P/B Ratio 1.52 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -81.16%
Market Cap 18.27 M Enterprise Value 1.38 M
Per Share
EPS (Diluted TTM) N/A Revenue / Share N/A
FCF / Share -0.94 OCF / Share -0.94
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 132.03%
SBC-Adj. FCF -15.28 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue — — — — —
Net Income -11.23 M -24.52 M -11.90 M -16.06 M -26.65 M
EPS (Diluted) — — -10.26 -2.21 —
Gross Profit — — -2.27 M — —
Operating Income -12.61 M -27.24 M -17.13 M -34.46 M -26.56 M
EBITDA — — — — —
R&D Expenses 6.60 M 6.10 M 7.10 M 6.93 M 14.20 M
SG&A Expenses — — — — —
D&A — 9,000.0 37,000.0 60,000.0 106,000.0
Interest Expense 185,000.0 653,000.0 498,000.0 12,000.0 93,000.0
Income Tax 0.0 -381,000.0 83,000.0 -1.52 M 133,000.0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 18.26 M 22.65 M 11.86 M 14.54 M 49.63 M
Total Liabilities 8.43 M 10.84 M 14.61 M 12.65 M 30.85 M
Shareholders' Equity 9.83 M 11.81 M -2.75 M -113,000.0 18.15 M
Total Debt — 2.69 M — 2.64 M —
Cash & Equivalents 14.69 M 19.53 M 166,000.0 — —
Current Assets 17.93 M 22.34 M 1.97 M 4.97 M 21.05 M
Current Liabilities 8.43 M 10.84 M 14.17 M 11.22 M 20.72 M